PFBT
CRNX icon

Parkside Financial Bank & Trust’s Crinetics Pharmaceuticals CRNX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.64K Sell
45
-15
-25% -$670 ﹤0.01% 2191
2025
Q4 		$2.79K Buy
60
+15
+33% +$668 ﹤0.01% 1989
2025
Q3 		$1.87K Sell
45
-2
-4% -$64 ﹤0.01% 2051
2025
Q2 		$1.35K Buy
47
+2
+4% +$62 ﹤0.01% 2139
2025
Q1 		$1.51K Buy
+45
New +$1.68K ﹤0.01% 1968

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Parkside Financial Bank & Trust's CRNX Position: Q1 2026 in Review

Parkside Financial Bank & Trust reduced its Crinetics Pharmaceuticals (CRNX) stake by 25% in Q1 2026, selling an estimated $670 and leaving 45 shares worth $1.64K. The position accounts for ﹤0.01% of the portfolio, ranked #2191.

Parkside Financial Bank & Trust first reported a position in CRNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.79K in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Parkside Financial Bank & Trust held 45 shares of Crinetics Pharmaceuticals worth $1.64K as of Q1 2026.
  • Parkside Financial Bank & Trust sold 15 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $670.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2191 holding.
  • Parkside Financial Bank & Trust first reported a position in Crinetics Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Parkside Financial Bank & Trust's Crinetics Pharmaceuticals position peaked at $2.79K in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.